小分子核酸药物在降脂治疗中的应用研究进展  

Advances in the application of small molecule nucleic acid drugs in lipid-lowering therapy

作　　者：叶江平 陈亮 宗刚军 YE Jiang-ping;CHEN Liang;ZONG Gang-jun(The Fifth Clinical College of Anhui Medical University,Wuxi 214044,China)

机构地区：[1]安徽医科大学第五临床学院,江苏省无锡市214044

出　　处：《中国心血管病研究》2023年第12期1133-1137,共5页Chinese Journal of Cardiovascular Research

基　　金：江苏省自然科学基金(BK20211043)。

摘　　要：动脉粥样硬化性心血管疾病当前排在全球死亡率前列,脂质或脂蛋白的异常是造成动脉粥样硬化的首要原因。他汀类药物等传统降脂药物疗效有时未能达到理想目标,残余心血管风险亟待解决。随着分子生物学的发展,小分子核酸药物凭借其独特的机制和优势,在降脂方面进行了许多研究,但对于不同靶点的研究还处于不同阶段。本文综述小分子核酸药物在降脂方面取得的研究进展。Atherosclerotic cardiovascular disease currently ranks as the leading cause of mortality in the world.The abnormalities in lipids or lipoproteins are the primary reason for atherosclerosis.The efficacy of traditional lipid-lowering drugs such as statins sometimes fails to meet the target,so residual cardiovascular risk needs to be urgently addressed.With the development of molecular biology,many relevant studies have been conducted on small molecule nucleic acid drugs in lipid lowering by virtue of their unique mechanisms and advantages,but the studies on different targets are still at different stages.In this article,The research progress of small molecule nucleic acid drugs in lipid lowering is reviewed.

关 键 词：小干扰核糖核酸 反义寡核苷酸 降脂疗法 

分 类 号：R541.4[医药卫生—心血管疾病]